Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that glycyrrhizic acid may reduce the cutaneous toxicity caused by Osimertinib in mice, suggesting its potential as an adjunct treatment in clinical settings.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

This study found that spironolactone enhanced the effectiveness of non-DNA-damaging cancer drugs gemcitabine and osimertinib in cancer cell lines and a mouse xenograft model, likely by suppressing the anti-apoptotic protein survivin.

This study demonstrates that a 3D-printed agarose microwell platform supports the growth of size-uniform, viable NSCLC cancer spheroids, and can effectively evaluate drug responses using limited tumor material from biopsies, particularly with EGFR tyrosine kinase inhibitors gefitinib and osimertinib.